ArticleTranslational cancer research2025
A novel manganese metabolism- and immune-related prognostic risk model for acute myeloid leukemia.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sample-Specific Generalized Cross-Validation for Gene Network Analysis of Cytarabine Response in Cancer Cell Lines.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Manganese (Mn), an essential trace element, is involved in various biological processes (BPs). The abnormal metabolism of Mn may be related to the occurrence and development of blood disease. In recent years, studies on manganese metabolism-related genes (MRGs) and acute myeloid leukemia (AML) have gradually attracted attention. The interaction between the immune system and AML is complex. The immune system not only participates in the occurrence and development of leukemia, but also affects the treatment response and prognosis of AML patients. This study aimed to establish a prognostic risk model for AML by combining MRGs and immune-related genes (IRGs). Methods: We constructed a prognostic risk model through univariate and multivariate Cox regression analyses, and validated the predictive efficacy of this model using external datasets. We analyzed the differences in immune infiltration between the high- and low-risk groups. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment analyses were conducted to investigate the roles of five Mn metabolism- and immune-related genes (MIRGs). We also analyzed the immune checkpoint expression levels in AML. The expression levels of the five MIRGs in specific cells were analyzed through single-cell RNA sequencing. All the data analyses were conducted using R software version 4.2.2. Results: This study developed a prognostic risk model based on five MIRGs ( Conclusions: Our study established an MIRG-based prognostic risk model that can effectively predict the prognosis of AML patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.